{"?xml":{"@version":"1.0"},"edm:RDF":{"@xmlns:dc":"http://purl.org/dc/elements/1.1/","@xmlns:edm":"http://www.europeana.eu/schemas/edm/","@xmlns:wgs84_pos":"http://www.w3.org/2003/01/geo/wgs84_pos","@xmlns:foaf":"http://xmlns.com/foaf/0.1/","@xmlns:rdaGr2":"http://rdvocab.info/ElementsGr2","@xmlns:oai":"http://www.openarchives.org/OAI/2.0/","@xmlns:owl":"http://www.w3.org/2002/07/owl#","@xmlns:rdf":"http://www.w3.org/1999/02/22-rdf-syntax-ns#","@xmlns:ore":"http://www.openarchives.org/ore/terms/","@xmlns:skos":"http://www.w3.org/2004/02/skos/core#","@xmlns:dcterms":"http://purl.org/dc/terms/","edm:WebResource":[{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:doc-KICDWDHJ/4c8f6c08-5ec7-41ae-acad-e63fd1d27716/HTML","dcterms:extent":"15 KB"},{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:doc-KICDWDHJ/de0eef32-14bc-43f3-91f5-33abca4f8caf/PDF","dcterms:extent":"52 KB"},{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:doc-KICDWDHJ/3d4ccf5f-1895-4d1e-b8db-74a120ff4525/TEXT","dcterms:extent":"14 KB"}],"edm:TimeSpan":{"@rdf:about":"1929-2026","edm:begin":{"@xml:lang":"en","#text":"1929"},"edm:end":{"@xml:lang":"en","#text":"2026"}},"edm:ProvidedCHO":{"@rdf:about":"URN:NBN:SI:doc-KICDWDHJ","dcterms:isPartOf":[{"@rdf:resource":"https://www.dlib.si/details/urn:nbn:si:spr-a30mfzkp"},{"@xml:lang":"sl","#text":"Zdravniški vestnik"}],"dcterms:issued":"2001","dc:creator":["Marin, Jožica","Strašek, Katja"],"dc:format":[{"@xml:lang":"sl","#text":"številka:6"},{"@xml:lang":"sl","#text":"letnik:70"},{"@xml:lang":"sl","#text":"str. 321-323"}],"dc:identifier":["ISSN:1318-0347","COBISSID:13587417","URN:URN:NBN:SI:doc-KICDWDHJ"],"dc:language":"en","dc:publisher":{"@xml:lang":"sl","#text":"Slovensko zdravniško društvo"},"dc:subject":[{"@xml:lang":"en","#text":"Antibodies, viral"},{"@xml:lang":"en","#text":"Antibody affinity"},{"@xml:lang":"en","#text":"diagnostika"},{"@xml:lang":"en","#text":"Herpesvirus 4, human"},{"@xml:lang":"en","#text":"IgG"},{"@xml:lang":"sl","#text":"protitelesa"},{"@xml:lang":"sl","#text":"virus Epstein-Barr"}],"dcterms:temporal":{"@rdf:resource":"1929-2026"},"dc:title":{"@xml:lang":"sl","#text":"Epstein-Barr virus infections - avidity test for IgG antibodies| Okužbe z virusom Epstein-Barr - določanje avidnosti protiteles IgG|"},"dc:description":[{"@xml:lang":"sl","#text":"Background. We wish to introduce specific IgG avidity test as a supplementary assay in serological screening for Epstein-Barr virus infection if the status of patient cannot be resolved from a single serum sample with routine testing.Methods. Avidity of IgG antibodies was determined in sera of 57 patients with different stage of Epstein-Barr virus infection. Enzyme-immunoassay was used with a short incubation of G-molar urea included in the procedure. Urea should remove low avtdity antibodies. Avidity was expressed as the avidity index: Avidity testing with commercial kit was done as well Results. Low avidity index was found for IgG antibodies of acute phasesera and high for those of past infection, recent infection and reactivation of endogenic virus. Conclusions. Avidity test for IgG antibodies might be supplementary assay toprove acute infection but also to resolve some other clinical states related to Epstein-Barr virus"},{"@xml:lang":"sl","#text":"Izhodišča. S testom avidnosti za določanje protiteles IgG proti različnim antigenom virusa Epstein-Barr želimo dopolniti diagnosticiranje okužb tedaj, ko z ustaljenimi preiskavnimi postopki ne moremo točno določiti stopnje okužbev enem serumu. Metode. V 57 serumih bolnikov z različnimi stopnjami okužbe z virusom Epstein-Barr smo določali avidnost protiteles IgG. V encimsko-imunski test smo po inkubaciji serumov z antigeni vključili kratko inkubacijo s 6-molarno ureo, ki odstrani nizko avidna protitelesa: Avidnost smo izrazili z indeksom avidnosti. Improvizirano metodo smo primerjali s standardiziranim komercialnim kompletom. Rezultati. Nizek indeks avidnosti protiteles IgG smo določili v serumih bolnikov z akutno okužbo, visokega pa v serumih bolnikov z okužbo v preteklosti, z nedavno okužbo in z reaktivacijo endogenega virusa. Zaključki. Test avidnosti protiteles IgG lahko predstavlja dopolnilno diagnostično metodo ne le pri potrditvi akutne okužbe, marveč tudi pri razjasnitvi drugih kliničnih oblik okužbe z virusom Epstein-Barr"}],"edm:type":"TEXT","dc:type":[{"@xml:lang":"sl","#text":"znanstveno časopisje"},{"@xml:lang":"en","#text":"journals"},{"@rdf:resource":"http://www.wikidata.org/entity/Q361785"}]},"ore:Aggregation":{"@rdf:about":"http://www.dlib.si/?URN=URN:NBN:SI:doc-KICDWDHJ","edm:aggregatedCHO":{"@rdf:resource":"URN:NBN:SI:doc-KICDWDHJ"},"edm:isShownBy":{"@rdf:resource":"http://www.dlib.si/stream/URN:NBN:SI:doc-KICDWDHJ/de0eef32-14bc-43f3-91f5-33abca4f8caf/PDF"},"edm:rights":{"@rdf:resource":"http://creativecommons.org/licenses/by-nc/4.0/"},"edm:provider":"Slovenian National E-content Aggregator","edm:intermediateProvider":{"@xml:lang":"en","#text":"National and University Library of Slovenia"},"edm:dataProvider":{"@xml:lang":"sl","#text":"Slovensko zdravniško društvo"},"edm:object":{"@rdf:resource":"http://www.dlib.si/streamdb/URN:NBN:SI:doc-KICDWDHJ/maxi/edm"},"edm:isShownAt":{"@rdf:resource":"http://www.dlib.si/details/URN:NBN:SI:doc-KICDWDHJ"}}}}